6:53 AM
 | 
Apr 01, 2019
 |  BC Extra  |  Clinical News

Apexigen's CD40 agonist shows response in pancreatic cancer

Over half of metastatic pancreatic cancer patients treated with Apexigen's APX005M as part of a combination regimen that included Opdivo nivolumab had a response, suggesting that the combination along with SOC could provide a new treatment option to an indication with little in the armamentarium.

An interim analysis of a Phase Ib trial for the regimen were presented at the American Association for Cancer Research (AACR) meeting on Sunday. In the study, the overall...

Read the full 347 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >